| Gary Rudolph, MD | |
|
Nsuh-dept Of Emergency Medicine, 300 Community Drive, Manhasset, NY 11030 | |
| (516) 562-3090 | |
| Not Available |
| Full Name | Gary Rudolph |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | Nsuh-dept Of Emergency Medicine, Manhasset, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164595476 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 150496 (New York) | Primary |
| Entity Name | Good Samaritan Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518901180 PECOS PAC ID: 5294639951 Enrollment ID: O20031124000491 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Entity Name | Mercy Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619245610 PECOS PAC ID: 4082518006 Enrollment ID: O20040210000431 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Entity Name | St Joseph Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881799153 PECOS PAC ID: 1254222938 Enrollment ID: O20040323000142 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Entity Name | St Francis Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760704811 PECOS PAC ID: 9234101221 Enrollment ID: O20040810001086 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Entity Name | Samaritan Emergency Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104978014 PECOS PAC ID: 7012016660 Enrollment ID: O20070621000503 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Entity Name | Progressive Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588098172 PECOS PAC ID: 8820225956 Enrollment ID: O20131218000289 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Entity Name | Long Island Community Hospital At Nyu Langone Health |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1508346248 PECOS PAC ID: 9739090051 Enrollment ID: O20190204000682 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gary Rudolph, MD Nsuh-dept Of Emergency Medicine, 300 Community Drive, Manhasset, NY 11030 Ph: (516) 562-3090 | Gary Rudolph, MD Nsuh-dept Of Emergency Medicine, 300 Community Drive, Manhasset, NY 11030 Ph: (516) 562-3090 |
News Archive
Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.
iView Systems, a leading provider of loss prevention solutions for the security and surveillance environment, today announced the availability of its latest version of iTrak, the award winning Incident Reporting & Risk Management platform.
A sedentary lifestyle can cause an impairment of the transport of blood around the body, which increases the risk of disease in the heart and blood vessels.
The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).
Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
› Verified 4 days ago
Annabella Salvador, Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 Community Drive, Nsuh-dept Of Emergency Medicine, Manhasset, NY 11030 Phone: 516-562-4125 | |
Jeffrey Greco, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Community Dr, Manhasset, NY 11030 Phone: 516-562-0100 | |
Ingrid Llovera, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Nsuh Dept Of Emergency Medicine, 300 Community Drive, Manhasset, NY 11030 Phone: 516-562-3090 | |
Dr. Rachel Shively, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Community Dr, Manhasset, NY 11030 Phone: 847-567-4404 | |
Dr. Justin Chen, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Community Dr, Manhasset, NY 11030 Phone: 516-562-2925 | |
Dr. Juan Camilo Mendez, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Community Dr, North Shore-lij Office Of Graduate Medical Education, Manhasset, NY 11030 Phone: 646-883-2290 Fax: 844-867-7210 | |
Ajay Kumar Puri, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 Community Drive, Concourse Level, Manhasset, NY 11030 Phone: 516-470-7873 |